 Upgrades Wedbush upgraded the previous rating for Best Buy Co Inc NYSE: BBY from Neutral to Outperform. For the first quarter, Best Buy Co had an EPS of 0.67, compared to year-ago quarter EPS of 1.02. At the moment, the stock has a 52-week-high of 111.39 and a 52-week-low of 48.10. Best Buy Co closed at 110.77 at the end of the last trading period. Cantor Fitzgerald upgraded the previous rating for Curaleaf Holdings Inc OTC: CURLF from Neutral to Overweight. Curaleaf Holdings earned 0.03 in the first quarter, compared to 0.02 in the year-ago quarter. The current stock performance of Curaleaf Holdings shows a 52-week-high of 9.66 and a 52-week-low of 2.54. Moreover, at the end of the last trading period, the closing price was at 9.43. For Barings BDC Inc NYSE: BBDC, Keefe, Bruyette Woods upgraded the previous rating of Market Perform to the current rating Outperform. For the second quarter, Barings BDC had an EPS of 0.14, compared to year-ago quarter EPS of 0.15. At the moment, the stock has a 52-week-high of 10.59 and a 52-week-low of 4.67. Barings BDC closed at 8.30 at the end of the last trading period. Downgrades According to Argus Research, the prior rating for Howmet Aerospace Inc NYSE: HWM was changed from Buy to Hold. Howmet Aerospace earned 0.12 in the second quarter, compared to 0.58 in the year-ago quarter. At the moment, the stock has a 52-week-high of 18.99 and a 52-week-low of 9.87. Howmet Aerospace closed at 17.35 at the end of the last trading period. For AMAG Pharmaceuticals Inc NASDAQ: AMAG, Barclays downgraded the previous rating of Overweight to the current rating Equal-Weight. AMAG Pharmaceuticals earned 0.57 in the second quarter, compared to 1.14 in the year-ago quarter. The stock has a 52-week-high of 13.53 and a 52-week-low of 4.41. At the end of the last trading period, AMAG Pharmaceuticals closed at 10.89. Oppenheimer downgraded the previous rating for Intercontinental Exchange Inc NYSE: ICE from Outperform to Perform. For the second quarter, Intercontinental Exchange had an EPS of 1.07, compared to year-ago quarter EPS of 0.94. The current stock performance of Intercontinental Exchange shows a 52-week-high of 104.30 and a 52-week-low of 63.51. Moreover, at the end of the last trading period, the closing price was at 104.07. For Montage Resources Corp NYSE: MR, Johnson Rice downgraded the previous rating of Buy to the current rating Hold. At the moment, the stock has a 52-week-high of 8.30 and a 52-week-low of 1.99. Montage Resources closed at 5.51 at the end of the last trading period. According to Citigroup, the prior rating for Nabors Industries Ltd NYSE: NBR was changed from Neutral to Sell. For the second quarter, Nabors Industries had an EPS of 14.45, compared to year-ago quarter EPS of 0.41. At the moment, the stock has a 52-week-high of 87.00 and a 52-week-low of 0.20. Nabors Industries closed at 46.45 at the end of the last trading period. For Unity Biotechnology Inc NASDAQ: UBX, Morgan Stanley downgraded the previous rating of Overweight to the current rating Equal-Weight. Unity Biotechnology earned 0.38 in the second quarter, compared to 0.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of 15.44 and a 52-week-low of 4.05. Unity Biotechnology closed at 4.15 at the end of the last trading period. Morgan Stanley downgraded the previous rating for Vonage Holdings Corp NASDAQ: VG from Overweight to Equal-Weight. Vonage Hldgs earned 0.04 in the second quarter, compared to 0.08 in the year-ago quarter. The current stock performance of Vonage Hldgs shows a 52-week-high of 13.66 and a 52-week-low of 4.18. Moreover, at the end of the last trading period, the closing price was at 11.77. SVB Leerink downgraded the previous rating for Principia Biopharma Inc NASDAQ: PRNB from Outperform to Market Perform. The current stock performance of Principia Biopharma shows a 52-week-high of 99.38 and a 52-week-low of 25.35. Moreover, at the end of the last trading period, the closing price was at 99.25. Initiations With a current rating of Outperform, Wedbush initiated coverage on Inozyme Pharma Inc NASDAQ: INZY. The price target seems to have been set at 35.00 for Inozyme Pharma. The current stock performance of Inozyme Pharma shows a 52-week-high of 31.27 and a 52-week-low of 17.25. Moreover, at the end of the last trading period, the closing price was at 29.00. Needham initiated coverage on Nurix Therapeutics Inc NASDAQ: NRIX with a Buy rating. The price target for Nurix Therapeutics is set to 35.00. The current stock performance of Nurix Therapeutics shows a 52-week-high of 27.64 and a 52-week-low of 15.21. Moreover, at the end of the last trading period, the closing price was at 27.00. Brookline Capital initiated coverage on 9 Meters Biopharma Inc NASDAQ: NMTR with a Buy rating. The price target for 9 Meters Biopharma is set to 5.00. 9 Meters Biopharma earned 0.57 in the second quarter, compared to 0.13 in the year-ago quarter. The stock has a 52-week-high of 0.82 and a 52-week-low of 0.44. At the end of the last trading period, 9 Meters Biopharma closed at 0.56. JP Morgan initiated coverage on ITeos Therapeutics Inc NASDAQ: ITOS with an Overweight rating. The price target for ITeos Therapeutics is set to 40.00. At the moment, the stock has a 52-week-high of 32.98 and a 52-week-low of 17.50. ITeos Therapeutics closed at 32.92 at the end of the last trading period. With a current rating of Buy, Citigroup initiated coverage on Digital Media Solutions Inc NYSE: DMS. The price target seems to have been set at 12.00 for Digital Media Solutions. At the moment, the stock has a 52-week-high of 10.66 and a 52-week-low of 6.75. Digital Media Solutions closed at 8.41 at the end of the last trading period. With a current rating of Buy, B of A Securities initiated coverage on Annexon Inc NASDAQ: ANNX. The price target seems to have been set at 33.00 for Annexon. The stock has a 52-week-high of 29.71 and a 52-week-low of 15.33. At the end of the last trading period, Annexon closed at 26.55. Wells Fargo initiated coverage on Voya Financial Inc NYSE: VOYA with an Overweight rating. The price target for Voya Finl is set to 62.00. For the second quarter, Voya Finl had an EPS of 1.09, compared to year-ago quarter EPS of 1.52. The stock has a 52-week-high of 63.81 and a 52-week-low of 29.75. At the end of the last trading period, Voya Finl closed at 51.22. B of A Securities initiated coverage on Inozyme Pharma Inc NASDAQ: INZY with a Buy rating. The price target for Inozyme Pharma is set to 33.00. At the moment, the stock has a 52-week-high of 31.27 and a 52-week-low of 17.25. Inozyme Pharma closed at 29.00 at the end of the last trading period. For Annexon Inc NASDAQ: ANNX, Cowen Co. initiated coverage, by setting the current rating at Outperform. The current stock performance of Annexon shows a 52-week-high of 29.71 and a 52-week-low of 15.33. Moreover, at the end of the last trading period, the closing price was at 26.55. With a current rating of Overweight, Piper Sandler initiated coverage on ITeos Therapeutics Inc NASDAQ: ITOS. The price target seems to have been set at 50.00 for ITeos Therapeutics. The current stock performance of ITeos Therapeutics shows a 52-week-high of 32.98 and a 52-week-low of 17.50. Moreover, at the end of the last trading period, the closing price was at 32.92. Piper Sandler initiated coverage on Seres Therapeutics Inc NASDAQ: MCRB with an Overweight rating. The price target for Seres Therapeutics is set to 40.00. In the second quarter, Seres Therapeutics showed an EPS of 0.28, compared to 0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of 33.00 and a 52-week-low of 2.52. Seres Therapeutics closed at 26.16 at the end of the last trading period. Needham initiated coverage on Personalis Inc NASDAQ: PSNL with a Buy rating. The price target for Personalis is set to 25.00. For the second quarter, Personalis had an EPS of 0.29, compared to year-ago quarter EPS of 0.89. The stock has a 52-week-high of 23.00 and a 52-week-low of 4.27. At the end of the last trading period, Personalis closed at 21.72.See more from Benzinga Forward Industries: Debt Overview Agilents Debt Overview Kohlss Debt OverviewC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 